Synovics Total Operating Expenses from 2010 to 2026
| SYVC Stock | USD 0.0001 0.00 0.00% |
Total Operating Expenses | First Reported 2010-12-31 | Previous Quarter 32.7 M | Current Value 21.5 M | Quarterly Volatility 6.7 M |
Check Synovics Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Synovics Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 0.0, Selling General Administrative of 6.7 M or Total Revenue of 31.3 M, as well as many indicators such as Price To Sales Ratio of 1.0E-4, Dividend Yield of 0.0 or PTB Ratio of 4.0E-4. Synovics financial statements analysis is a perfect complement when working with Synovics Pharmaceuticals Valuation or Volatility modules.
Synovics | Total Operating Expenses | Build AI portfolio with Synovics Stock |
Analyzing Synovics Pharmaceuticals's Total Operating Expenses over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Total Operating Expenses has evolved provides context for assessing Synovics Pharmaceuticals's current valuation and future prospects.
Latest Synovics Pharmaceuticals' Total Operating Expenses Growth Pattern
Below is the plot of the Total Operating Expenses of Synovics Pharmaceuticals over the last few years. It is the total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses. Synovics Pharmaceuticals' Total Operating Expenses historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Synovics Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Total Operating Expenses | 10 Years Trend |
|
Total Operating Expenses |
| Timeline |
Synovics Total Operating Expenses Regression Statistics
| Arithmetic Mean | 26,726,170 | |
| Geometric Mean | 24,073,890 | |
| Coefficient Of Variation | 25.09 | |
| Mean Deviation | 3,531,713 | |
| Median | 28,443,044 | |
| Standard Deviation | 6,706,352 | |
| Sample Variance | 45T | |
| Range | 30.8M | |
| R-Value | 0.34 | |
| Mean Square Error | 42.3T | |
| R-Squared | 0.12 | |
| Significance | 0.18 | |
| Slope | 457,381 | |
| Total Sum of Squares | 719.6T |
Synovics Total Operating Expenses History
About Synovics Pharmaceuticals Financial Statements
Synovics Pharmaceuticals stakeholders use historical fundamental indicators, such as Synovics Pharmaceuticals' Total Operating Expenses, to determine how well the company is positioned to perform in the future. Although Synovics Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Synovics Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Synovics Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Synovics Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Total Operating Expenses | 32.7 M | 21.5 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Synovics Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Synovics Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Synovics Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Synovics Pharmaceuticals Stock:Check out the analysis of Synovics Pharmaceuticals Correlation against competitors. For information on how to trade Synovics Stock refer to our How to Trade Synovics Stock guide.You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Will Pharmaceuticals sector continue expanding? Could Synovics diversify its offerings? Factors like these will boost the valuation of Synovics Pharmaceuticals. If investors know Synovics will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Synovics Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding Synovics Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects Synovics's accounting equity. The concept of intrinsic value - what Synovics Pharmaceuticals' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Synovics Pharmaceuticals' price substantially above or below its fundamental value.
Please note, there is a significant difference between Synovics Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Synovics Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Synovics Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.